Oppenheimer Maintains an 'Outperform' on Keryx Biopharmaceuticals (KERX); Opportunities for Zerenex
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Price: $8.03 --0%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 13
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 13
Trade KERX Now!
Oppenheimer maintains an 'Outperform' on Keryx Biopharmaceuticals (NASDAQ: KERX) price target of $3.00.
Analyst, Boris Peaker, said, "We attended the Keryx analyst day yesterday and came away feeling that the company is well positioned to execute on its clinical and strategic plans. Moreover we continue to view the market potential for Zerenex as underappreciated and the shares of KERX having a favorable risk/reward ratio over the next 12-18 months. Three takeaways from the analyst day we highlight are: (1) there is significant patient dissatisfaction with available phosphate binders and cycling through available drugs; (2) there is potential for Zerenex to be used treating pre-dialysis patients; and (3) a new study to potentially extend the pill burden advantage with Zerenex will start soon."
Peaker lowers Q4 EPS estimate from $0.07 to (0.06) and FY12 from (0.20) to (0.34)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.82 yesterday, with a 52 week range of $1.28-$5.19.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Boris Peaker, said, "We attended the Keryx analyst day yesterday and came away feeling that the company is well positioned to execute on its clinical and strategic plans. Moreover we continue to view the market potential for Zerenex as underappreciated and the shares of KERX having a favorable risk/reward ratio over the next 12-18 months. Three takeaways from the analyst day we highlight are: (1) there is significant patient dissatisfaction with available phosphate binders and cycling through available drugs; (2) there is potential for Zerenex to be used treating pre-dialysis patients; and (3) a new study to potentially extend the pill burden advantage with Zerenex will start soon."
Peaker lowers Q4 EPS estimate from $0.07 to (0.06) and FY12 from (0.20) to (0.34)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.82 yesterday, with a 52 week range of $1.28-$5.19.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
